Set of genes predicts severity of dengue

Set of genes predicts severity of dengue

There's no such thing as a "good" case of dengue fever, but some are worse than others, and it's difficult to determine which patients will make a smooth recovery and which may find their condition life-threatening.

Now, after scouring the gene expression of hundreds of patients infected with dengue virus -- a mosquito-borne virus that can cause fever and joint pain, among other symptoms -- scientists have found a set of 20 genes that predicts who is at the highest risk of progressing to a severe form of the illness.

Every year, between 200 million and 400 million people in tropical and subtropical regions of the world contract dengue fever, and about 500,000 of those cases are fatal. For the most part, people with the disease recover after receiving some fluids and a few days' rest, said the co- senior author. "But there's a smaller subset of patients who get severe dengue, and right now we don't know how to tell the difference."

Anywhere from 5 to 20 percent of dengue cases will advance to severe. Currently, the standard of care boils down to watching and waiting: To diagnose severe dengue, doctors wait to observe specific symptoms and results of laboratory tests that typically emerge in the late stages of the disease. "These practices are not nearly sensitive or accurate enough, and some patients end up admitted to the hospital unnecessarily, while others are discharged prematurely," said said the other co-senior author.

Using their newly identified set of genes as a foundation, researchers aim to identify predictive biomarkers that can help doctors reliably gauge the likelihood of severe dengue in patients who are newly symptomatic and use that information to provide more accurate care to help guide therapeutic clinical studies and, in the future, to guide treatment decisions.

Adept at sleuthing out new findings from old data, researchers used five previously published papers, which reported information on about 450 individuals collectively, to identify the severe-dengue gene set. Each study catalogued groups of dengue patients, tracking the "transcriptome," or record of gene expression, at the onset of symptoms for each case.

"The papers had data on dengue patients from multiple countries. We looked at the data and asked, 'Irrespective of the patient's genetic background, age and the genetics of the dengue virus itself -- different regions have different forms of dengue -- what is the molecular response that always shows up when you have a dengue infection?'" the co-senior author said. "But we weren't comparing healthy versus infected patients; we compared those who had an uncomplicated dengue infection with those who developed severe dengue."

In analyzing data from the five studies, the authors identified 20 genes that stood out. In all of the patients who developed severe dengue, these genes showed a specific expression pattern, or signature: Seventeen were underexpressed, whereas three were overactive. But predicting severe dengue is more complex than whether patients expressed this pattern; there's variability. Some of the genes were down-regulated to a greater extent in some patients, and less so in others; likewise, there was variability in the degree of overactivity in the overexpressed genes.

To make sense of the continuum, the researchers developed a score that accounted for this gene-expression variability, essentially evaluating the patients' risk for severe dengue based on dips and piques of expression in these 20 genes. The higher the score, the higher the risk of severe dengue.

Then they tested their dengue-prediction method on data from three separate, previously published cohorts of dengue patients, whose transcriptome data was public, and found that the 20-gene set predicted 100 percent of the patients who developed severe dengue. Among those predicted to come down with severe dengue, 78 percent did.

Next, the researchers wanted to see if their predictive measure would succeed in a real-world patient population. So in partnership with the Clinical Research Center of the Valle del Lili Foundation, in Colombia, they set up a prospective cohort of 34 participants with dengue to assess the efficacy of the predictive gene markers. Each of participants' transcriptome information, which came from a simple blood draw, yielded a predictive score based on the 20-gene set, and again, the researchers saw the same levels of accuracy in their test: The test predicted the participants with severe dengue, and there were only a few patients predicted to develop severe dengue who did not. The researchers plan to conduct larger trials as they aim to bring the evaluation into clinical use. They're already expanding trials into Paraguay.